Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 07, 2019 07:00 ET | Source: Verrica Pharmaceuticals Inc.

Verrica Appoints Neil D. DeHenes as Vice President of Distribution, Trade and Channel Strategy

WEST CHESTER, Pa., Jan. 07, 2019 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a pharmaceutical company focused on identifying, developing and commercializing...
January 03, 2019 06:30 ET | Source: Verrica Pharmaceuticals Inc.

Verrica Achieves Positive Topline Results from Two Pivotal Phase 3 Clinical Trials of VP-102 in Patients with Molluscum Contagiosum

CAMP-1 and CAMP-2 Phase 3 pivotal trials for molluscum contagiosum both achieve statistical significance for the primary endpoint with p-values less than 0.0001 No serious adverse events in VP-102...
November 07, 2018 16:32 ET | Source: Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Reports Third Quarter 2018 Financial Results

WEST CHESTER, Pa., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a pharmaceutical company focused on identifying, developing and commercializing...
November 01, 2018 16:05 ET | Source: Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Announces Participation in the Jefferies 2018 London Healthcare Conference

WEST CHESTER, Pa., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a pharmaceutical company focused on identifying, developing and commercializing innovative...
September 24, 2018 07:05 ET | Source: Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Inc. Announces Inclusion in Russell 2000® and Russell 3000® Indexes

WEST CHESTER, Pa., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a pharmaceutical company focused on identifying, developing and commercializing...
September 12, 2018 16:05 ET | Source: Verrica Pharmaceuticals Inc.

Verrica Announces Successful Phase 2 Innovate Trial and Complete Enrollment of Phase 3 Trials of VP-102 in Molluscum Contagiosum Ahead of Schedule

Innovate trial results reaffirm Phase 3 protocol design No serious adverse events (SAEs) reported during the Innovate trial Phase 3 pivotal trials for molluscum contagiosum fully enrolled and...
August 15, 2018 06:50 ET | Source: Verrica Pharmaceuticals Inc.

Verrica Appoints Neetu Dhaliwal as Vice President of Business Development

WEST CHESTER, Pa., Aug. 15, 2018 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a pharmaceutical company focused on identifying, developing and commercializing...
August 07, 2018 16:01 ET | Source: Verrica Pharmaceuticals Inc.

Verrica Reports Second Quarter 2018 Financial Results

WEST CHESTER, Pa., Aug. 07, 2018 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a pharmaceutical company focused on identifying, developing and commercializing...
June 19, 2018 16:05 ET | Source: Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Inc. Announces Closing of Initial Public Offering

WEST CHESTER, Pa., June 19, 2018 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq:VRCA), a pharmaceutical company focused on identifying, developing and commercializing...
June 14, 2018 17:52 ET | Source: Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Inc. Announces Pricing of Initial Public Offering

WEST CHESTER, Pa., June 14, 2018 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq:VRCA), a pharmaceutical company focused on identifying, developing and commercializing...